Alto Neuroscience, Inc. (ANRO) Form 10-Q — Aug 12, 2026
Alto Neuroscience (ANRO) filed its Q2 2026 10-Q reporting a net loss of $27.6 million (EPS -$0.65), up from $17.7 million a year ago, as R&D spend jumped to $22.1 million from $13.1 million, driven mainly by the ALTO-207 Phase 2b launch in treatment-resistant depression. Balance sheet remains well funded: $244.2 million in cash and restricted cash at June 30, 2026, bolstered after quarter-end by $94.6 million net from a July offering priced at $26.48 per share. Management states existing cash plus the July raise and anticipated Wellcome proceeds fund operations for at least the next 12 months; shares outstanding rose to 39.2 million by August 7 from 31.9 million at year-end.
Key figures
- Total Debt
- 15000000
- Total Assets
- 254066000
- Cash Position
- 243733000
- Shares Outstanding
- 39242104
- March 2026 pipe
- $120.0M gross / $114.8M net at $20.00 per share
- October 2025 pipe
- ~$50.0M gross / $49.7M net at $5.9140 per share
- Ga expense q2 2026
- 7021000
- July 2026 offering
- 3,776,436 shares at $26.48; ~$94.6M net (closed July 14, 2026)
- Rd expense q2 2025
- 13124000
- Rd expense q2 2026
- 22108000
- Accumulated deficit
- 255509000
- K2 facility capacity
- 75000000
- Chase milestone potential
- up to $71.5M ($41.0M commercial); $2.0M paid May 2026
- Wellcome convertible grant drawn
- 2000000
- Term loan weighted avg rate q2 2026
- 12.22%
- Wellcome convertible grant capacity
- 11700000
- Shares issued outstanding jun 30 2026
- 35093940
Price after filing
Close on the filing date to close N calendar days later (from $29.18). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.